Trial Profile
A Phase III, Multi-center, Single-dose, Randomized, Double-blind, Non-inferiority and Lot-to-lot Consistency Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) versus Fluarix Tetra Vaccine in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2017
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary) ; GSK 2321138A
- Indications Influenza virus infections
- Focus Therapeutic Use
- Sponsors Adimmune Corporation
- 10 May 2017 Status changed from recruiting to completed, according to an Adimmune Corporation media release.
- 23 Nov 2016 According to an Adimmune Corporation media release, company begin the process for a Biologics License Application (BLA) in 2017.
- 09 Nov 2016 New trial record